Altering Patient Treatment: How Subcutaneous Delivery Can Help Patients Manage Chronic Conditions

By Victoria Morgan, West Pharmaceutical Services, Inc.

SIS_SelfDose_042 _1252_RGB

In recent years, the pharmaceutical industry has seen a steady shift toward increased patient centricity. The impact can be seen in nearly every aspect of the industry – from regulatory guidance, trial design, and drug delivery to new drugs proliferating the pipeline, such as biologics. Biologics are helping to revolutionize the treatment of chronic diseases such as multiple sclerosis and other autoimmune diseases, by helping patients take less frequent injections.

Additionally, by targeting specific components of a disease in ways never thought possible before, these therapies may also help some acute conditions, including certain types of cancer, become manageable chronic conditions.

A real focus of biologics research and development lies in new molecular entities which can be administered into the sub-cutaneous tissue in the skin. Therapeutic areas such as growth hormones and diabetes have long shown efficacy through sub-cutaneous delivery and an established patient acceptance of self-injection and pain tolerance. These therapeutic areas are rapidly being joined by oncology, autoimmune and blood disorders which traditionally had IV and infusion are the main routes of administration, but which are now seeing novel drug launches with sub-cutaneous delivery routes.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Med Device Online? Subscribe today.

Subscribe to Med Device Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Med Device Online

West Pharmaceutical Services, Inc.